Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review

Date: April 26, 2017
Pages: 71
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G7A3D62774BEN
Leaflet:

Download PDF Leaflet

Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review
Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA Key Recent Developments

Apr 17,2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program
Apr 07,2017: Grifols participates at the 3rd International Conference on Research into Alpha-1 Antitrypsin Deficiency, and the 6th International Congress of Alpha-1 Patients
Feb 28,2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division
Nov 08,2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million
Oct 20,2016: The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Both Serology and Molecular Tests

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Grifols SA - Key Facts
Grifols SA - Key Employees
Grifols SA - Key Employee Biographies
Grifols SA - Major Products and Services
Grifols SA - Pharmaceutical Pipeline Products Data
Grifols SA, Pipeline Products by Therapy Area
Grifols SA, Pipeline Products by Development Phase
Grifols SA - History
Grifols SA - Company Statement
Grifols SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Grifols SA - Business Description
Grifols SA - Corporate Strategy
Grifols SA - SWOT Analysis
SWOT Analysis - Overview
Grifols SA - Strengths
Grifols SA - Weaknesses
Grifols SA - Opportunities
Grifols SA - Threats
Grifols SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Grifols SA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 17, 2017: Grifols Donates 140 Million International Units of Blood Clotting Factors to the World Federation of Hemophilia Humanitarian Aid Program
Apr 07, 2017: Grifols participates at the 3rd International Conference on Research into Alpha-1 Antitrypsin Deficiency, and the 6th International Congress of Alpha-1 Patients
Feb 28, 2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division
Nov 08, 2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million
Oct 20, 2016: The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Both Serology and Molecular Tests
Jul 28, 2016: Sales of the Bioscience Division grow by +7.0%, increasing Grifols' revenues by +2.7% to EUR 1,952 million
Jul 05, 2016: Pedigri: the tool that increases the information transparency to the plasma-derived manufactured in Clayton
Jun 16, 2016: Grifols confirms that it has voluntarily signed the EFPIA Code of Conduct
May 19, 2016: Announcing the fourth Annual National Hemophilia Foundation Annual Meeting Pre-Conference Symposium
May 05, 2016: Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the Bioscience Division

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Grifols SA, Key Facts
Grifols SA, Key Employees
Grifols SA, Key Employee Biographies
Grifols SA, Major Products and Services
Grifols SA, Number of Pipeline Products by Therapy Area
Grifols SA, Number of Pipeline Products by Development Stage
Grifols SA, History
Grifols SA, Other Locations
Grifols SA, Subsidiaries
Grifols SA, Key Competitors
Grifols SA, Ratios based on current share price
Grifols SA, Annual Ratios
Grifols SA, Annual Ratios (Cont.1)
Grifols SA, Annual Ratios (Cont.2)
Grifols SA, Interim Ratios
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Grifols SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Grifols SA, Pipeline Products by Therapy Area
Grifols SA, Pipeline Products by Development Phase
Grifols SA, Performance Chart (2012 - 2016)
Grifols SA, Ratio Charts
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Oryzon Genomics SA
HemaCare Corp
CSL Ltd
Abeona Therapeutics Inc
AB-Biotics SA
Skip to top


Ask Your Question

Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: